Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

Inclusion Criteria: * able to understand the study and provide written informed consent * be age 18 to 49 years * be in good general health, without significant medical history, physical examination findings, or abnormal laboratory results * be available for the study duration, including all planned follow-up visits * female subjects of child bearing potential must not be pregnant and agree to be correctly using an efficacious hormonal method of contraception or intrauterine device for at least 1 month before the study and during the study Exclusion Criteria: * have allergy to eggs or other components of the vaccine * have had an influenza vaccine within 3 years preceding the screening visit * have a history of severe reaction of any kind to conventional influenza vaccines * have or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized malignancy, or treatment with immunosuppressive medications, including corticosteroids, alkylating agents, antimetabolites, or radiation therapy * have a history of an autoimmune disorder, including systemic lupus, rheumatoid arthritis, scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis limited to cutaneous manifestations is not an exclusion criterion. * have prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs * have had transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 3 months of the Screening Visit or anticipated through the study period * have received another vaccine within 30 days preceding the screening visit or anticipated through the study period * have participation in another clinical trial within 60 days of the screening visit * have a positive serum or urine pregnancy test prior to vaccination or plan on a pregnancy during study period * have abnormalities on laboratory assessment * be seropositive to HIV or HCV or positive for HBsAg * be positive for anti-nuclear antibodies * have a physical examination indicating any clinically significant medical condition * have a body temperature \>38.1°C (100.6°F) or acute illness within 3 days prior to vaccination * intention to travel out of the area prior to the study visit on Day 28 of the study * have a history of excessive alcohol consumption, drug abuse, significant psychiatric illness * have the intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting or to initiate vigorous exercise from Screening until after Day 28 of the study